If you have been reading about BPC-157 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-06-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Freeze-dried solid, often hygroscopic |
| Solubility class | Freely soluble in water | Aqueous buffers used for stock solutions |
| Storage, dry powder | Minus 20 °C or colder | Recommended for long-term retention |
| Storage, solution | 2–8 °C or frozen | Avoid repeated freeze-thaw cycles |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity percentage plus mass confirmation |
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
Lyophilized material is generally kept cold, commonly at minus twenty degrees Celsius, and shielded from moisture and light. Solutions are less stable than the dry powder, so repeated freeze-thaw cycles are avoided by splitting the material into single-use portions. Published stability data for this particular peptide are limited, which means suggested hold times should be read as provisional. Long-term refrigeration of reconstituted solutions is not well supported by available evidence.
Identity and purity are checked with standard peptide techniques. Reversed-phase high-performance liquid chromatography separates the main peak from closely related impurities and yields a percentage purity. Mass spectrometry confirms that the measured mass matches the theoretical value. Amino acid analysis offers an independent check on overall composition. These analytical methods characterize the material itself and reveal nothing about how it behaves in a living system.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Beispiele für Anwendungen sind die Gebiete der Biotechnologie, Proteinforschung, Entwicklung von Medikamenten, Blutuntersuchungen (Cholesterol-Gehalt), Analyse von Lebensmitteln, Prozesskontrolle und Aufspürung von chemischen und nuklearen Kampfstoffen. Bruker-Standorte in Deutschland sind: Ettlingen (Stammsitz Bruker BioSpin, Bruker Optics, Bruker BioSpin MRI), Karlsruhe (Bruker AXS), Bremen (Bruker Daltonics), Berlin (Bruker Nano Analytics), Leipzig (Bruker Optics) und Hanau (Bruker EAS).
=== Die 1960er Jahre === Am 7. September 1960 kam es zur Gründung der Bruker Physik-AG durch Günther Laukien, damals Professor für Experimentalphysik an der Universität Karlsruhe. Da in dieser Zeit Universitätsprofessoren in Deutschland nicht zugleich auch in kommerziellen Unternehmen arbeiten durften, erhielt die Firma den Namen des Mitbegründers Emil Bruker. Zuerst wurden im Hinterhof eines Gebäudes in der Hardtstraße in Karlsruhe Labormagnete und deren Gleichstromnetzgeräte produziert. 1963 beschäftigte die Firma rund 30 Mitarbeiter und brachte ihre ersten hochauflösenden NMR- und ESR-Spektrometer auf den Markt. Im Jahr 1964 wurden die neugebauten Labors und Produktionsstätten in Rheinstetten in der Nähe von Karlsruhe bezogen. In diesen Jahren entwickelte und baute man die weltweit ersten kommerziell erhältlichen NMR-Pulsspektrometer, die vor allem an Kunden in europäischen Universitäten verkauft wurden. Parallel dazu wurde bei Bruker Physik-AG die Entwicklung von großen, ein sehr homogenes Magnetfeld liefernden (hochauflösenden) Elektromagneten, mit Netzgeräten extremer Stabilität, wie sie die NMR- und ESR-Spektroskopie verlangt, gestartet. Dabei profitierte Bruker wie auch andere Unternehmen von der damaligen Förderpolitik der Deutschen Forschungsgemeinschaft (DFG) für die Anschaffung von Großgeräten.
Gleichzeitig zu den Aktivitäten bei Bruker betrieb in Zürich die Firma Trüb-Täuber & Co eine kleine Forschungsabteilung um Werner Tschopp und Tony Keller für die Entwicklung von NMR-Spektrometern. Die NMR-Forschung bei Trüb-Täuber profitierte von einer engen Zusammenarbeit mit der ETH Zürich, insbesondere mit den Professoren Hans H. Günthard und Hans Primas sowie mit Richard R. Ernst, der 1991 den Nobelpreis für Chemie erhielt. Das erste Trüb-Täuber-System, KIS I, basierte auf einem Permanentmagneten und arbeitete bei 25 MHz. Mitte der 1960er Jahre geriet Trüb-Täuber in wirtschaftliche Schwierigkeiten. Um den Weiterbestand der NMR-Abteilung zu sichern, gründete G. Laukien zusammen mit Werner Tschopp und Tony Keller ein neues Unternehmen: die Spectrospin AG in Zürich. Die kleine Firma beschäftigte in Zürich-Altstetten ein halbes Dutzend Ingenieure, Physiker und Elektroniker sowie ein paar Mechaniker. Die Gründung der Spectrospin AG schuf die Rahmenbedingungen für eine Kooperation mit Synergieeffekten. Spectrospin baute die hochauflösenden NMR-Instrumente. Bruker lieferte die leistungsstarken Magnete. Jedes Gerät war eine Einzelfertigung und gleichzeitig ein Prototyp. Eingesetzt wurden die Geräte in Universitäten und in Forschungseinrichtungen der chemischen Industrie. Ein Gerät kostete damals etwa 1 Mio. CHF. Gemeinsam nahmen die beiden Unternehmen ein ehrgeiziges gemeinsames Entwicklungsprojekt in Angriff, dessen Resultat ein neuartiges, vollständig mit Transistoren arbeitendes NMR-Spektrometer war.
Das erste dieser Instrumente mit der Bezeichnung HFX 90 wurde an die Technische Universität Berlin geliefert. Mit dem HFX 90 kam erstmals ein kommerzielles Spektrometer mit drei separaten Kanälen auf den Markt – je einem Kanal für Signalerkennung, Entkopplung und Lock. Damit konnten völlig neue Experimente durchgeführt werden, und bisher komplexe Experimente wurden zur Routine. Bruker konzentrierte sich damals auf Magnete, NMR-Impulsspektrometer, ESR- und Netzgeräte.
Sources: de.wikipedia.org
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.
Reverse-phase liquid chromatography is used to assess purity, and mass spectrometry confirms molecular mass. Together these two checks form the most widespread approach. Some laboratories add amino acid analysis for further verification.
Yes. The peptide is freely soluble in water and in aqueous buffers, so reconstitution does not require an organic solvent. Stock solutions are usually prepared in water or a mild buffer. Exact handling depends on the intended downstream application.
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.